# Phase 2 acceptance record

**Reviewed code checkpoint:** `5414343`
**Acceptance authority:** Project owner
**Decision: PHASE 2 IS ACCEPTED.**

## Evidence

| Criterion | Result |
|---|---|
| Scope | Patient identity, demographics, contacts, relationships, and lifecycle only; no clinical, scheduling, billing, or production scope added |
| Local reconstruction | `db:start:local`, `db:reset:local`, and `db:provision:local` passed using committed migrations and synthetic seed data |
| Database authorization | 15 local pgTAP suites passed, including tenant isolation, grants, RLS, RPC, audit, and patient lifecycle coverage |
| Concurrency | Three local patient create/demographics/child-write concurrency suites passed |
| Application checks | Lint, typecheck, and 370 unit tests passed on the composed Phase 2 checkpoint |
| Policy | ADR-020 was amended on 2026-08-26 to make local verification the Phase 2 closeout gate |

## Deferred pre-production gate

Guarded Cloud TEST remains mandatory immediately before production deployment.
That gate must verify hosted migrations, generated types, managed Auth posture,
security advisors, and synthetic Playwright MFA journeys against the designated
Cloud TEST project. Production patient use also remains blocked by the security
architecture's separate production gates.

## Decision

**Phase 2 Patient Foundation is accepted as of 2026-08-26.** This acceptance is
based on the owner-approved local closeout policy and recorded synthetic local
verification. It is not approval for production patient use.
